Morgan Stanley lowered the firm’s price target on Biogen (BIIB) to $152 from $157 and keeps an Equal Weight rating on the shares. The firm ...

Shares of Biogen Inc. BIIB slipped 5.90% to $113.38 Thursday, on what proved to be an all-around rough trading session for ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Shares of Biogen Inc. BIIB shed 3.08% to $119.19 Monday, on what proved to be an all-around grim trading session for the ...

But that doesn't mean long term investors can avoid big losses. For example the Biogen Inc. (NASDAQ:BIIB) share price dropped 56% over five years. That's an unpleasant experience for long term ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neuroscience and neurodegenerative diseases with a market capitalization of $17.45 billion, finds itself at a critical ...

Biogen recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, despite these ...

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080 ...

Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint New building will be ...

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company currently trading near its 52-week low and considered undervalued by InvestingPro analysts, announced today that the U.S ...

Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar ...

UK pharmaceutical leaders from Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda ...